0.12(1.71%) Volume: 7,907 10:00AM EDT| Market Cap : 264.91 M | Enterprise Value : 171.1 M | P/E (TTM) : 4.29 | P/B : 3.21 |
|---|
AVDL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVDL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 352.34 |
AVDL's Cash-to-Debt is ranked higher than
51% of the 1056 Companies in the Global Biotechnology industry. ( Industry Median: 73.06 vs. AVDL: 352.34 ) Ranked among companies with meaningful Cash-to-Debt only. |
AVDL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 9.51 Max: 352.34 Current: 352.34 |
| Equity-to-Asset | 0.34 |
AVDL's Equity-to-Asset is ranked lower than
81% of the 770 Companies in the Global Biotechnology industry. ( Industry Median: 0.68 vs. AVDL: 0.34 ) Ranked among companies with meaningful Equity-to-Asset only. |
AVDL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08 Med: 0.53 Max: 0.8 Current: 0.34 |
| Interest Coverage | 57.99 |
AVDL's Interest Coverage is ranked lower than
72% of the 521 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. AVDL: 57.99 ) Ranked among companies with meaningful Interest Coverage only. |
AVDL'
s Interest Coverage Range Over the Past 10 Years
Min: 46.02 Med: 52.01 Max: 57.99 Current: 57.99 |
| Piotroski F-Score: 6 |
|
| Altman Z-Score: 1.60 |
|
| Beneish M-Score: -1.94 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | 35.21 |
AVDL's Operating Margin % is ranked higher than
98% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -98.02 vs. AVDL: 35.21 ) Ranked among companies with meaningful Operating Margin % only. |
AVDL'
s Operating Margin % Range Over the Past 10 Years
Min: -611.75 Med: -28.65 Max: 58.79 Current: 35.21 |
| Net Margin % | 39.41 |
AVDL's Net Margin % is ranked higher than
95% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -88.19 vs. AVDL: 39.41 ) Ranked among companies with meaningful Net Margin % only. |
AVDL'
s Net Margin % Range Over the Past 10 Years
Min: -1027.16 Med: -27.32 Max: 39.41 Current: 39.41 |
| ROE % | 94.84 |
AVDL's ROE % is ranked higher than
99% of the 969 Companies in the Global Biotechnology industry. ( Industry Median: -40.23 vs. AVDL: 94.84 ) Ranked among companies with meaningful ROE % only. |
AVDL'
s ROE % Range Over the Past 10 Years
Min: -1111.21 Med: -23.96 Max: 106.97 Current: 94.84 |
| ROA % | 26.38 |
AVDL's ROA % is ranked higher than
98% of the 1062 Companies in the Global Biotechnology industry. ( Industry Median: -32.55 vs. AVDL: 26.38 ) Ranked among companies with meaningful ROA % only. |
AVDL'
s ROA % Range Over the Past 10 Years
Min: -58.85 Med: -12.24 Max: 27.38 Current: 26.38 |
| ROC (Joel Greenblatt) % | 2890.38 |
AVDL's ROC (Joel Greenblatt) % is ranked higher than
99% of the 1021 Companies in the Global Biotechnology industry. ( Industry Median: -430.94 vs. AVDL: 2890.38 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
AVDL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4050.11 Med: -42.51 Max: 3538.48 Current: 2890.38 |
| 3-Year Revenue Growth Rate | 115.60 |
AVDL's 3-Year Revenue Growth Rate is ranked higher than
98% of the 604 Companies in the Global Biotechnology industry. ( Industry Median: 4.00 vs. AVDL: 115.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
AVDL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4 Med: 0.8 Max: 181.1 Current: 115.6 |
| Charles Brandes 3,308,250 sh (New) Jim Simons 1,144,600 sh (+38.96%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| Charles Brandes | 2018-03-29 | Add 45.35% | 0.22% |  $7.29 | $ 7.13 | -2% | 4,808,493 |  |
| Charles Brandes | 2017-12-31 | New Buy | 0.55% | $8.03 - $11.25 | $ 7.13 | -24% | 3,308,250 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!! What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 | |
|---|---|---|
| Compare: | NAS:ARDX, MIL:MLM, NAS:MLNT, NAS:CASI, NAS:ATHX, NAS:CDXC, OSL:BGBIO, XKRX:007630, NAS:NLNK, NAS:CMRX, NAS:FBIO, NAS:CALA, NAS:BLCM, NAS:OCUL, ASX:PNV, AMEX:AMPE, OTCPK:AXIM, ROCO:6586, NAS:NERV, OTCPK:ELOX » details | |
| Traded in other countries: | AWK1.Germany, | |
| Headquarter Location: | Ireland |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PE Ratio | 4.29 |
AVDL's PE Ratio is ranked higher than
91% of the 260 Companies in the Global Biotechnology industry. ( Industry Median: 29.83 vs. AVDL: 4.29 ) Ranked among companies with meaningful PE Ratio only. |
AVDL'
s PE Ratio Range Over the Past 10 Years
Min: 4.22 Med: 11.42 Max: 33.65 Current: 4.29 |
| PE Ratio without NRI | 4.29 |
AVDL's PE Ratio without NRI is ranked higher than
92% of the 255 Companies in the Global Biotechnology industry. ( Industry Median: 30.45 vs. AVDL: 4.29 ) Ranked among companies with meaningful PE Ratio without NRI only. |
AVDL'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.22 Med: 11.42 Max: 33.65 Current: 4.29 |
| Price-to-Owner-Earnings | 10.47 |
AVDL's Price-to-Owner-Earnings is ranked higher than
91% of the 148 Companies in the Global Biotechnology industry. ( Industry Median: 36.07 vs. AVDL: 10.47 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
AVDL'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.96 Med: 19.07 Max: 537.22 Current: 10.47 |
| PB Ratio | 3.21 |
AVDL's PB Ratio is ranked higher than
63% of the 954 Companies in the Global Biotechnology industry. ( Industry Median: 4.51 vs. AVDL: 3.21 ) Ranked among companies with meaningful PB Ratio only. |
AVDL'
s PB Ratio Range Over the Past 10 Years
Min: 1.84 Med: 4.76 Max: 71.87 Current: 3.21 |
| PS Ratio | 1.69 |
AVDL's PS Ratio is ranked higher than
89% of the 733 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. AVDL: 1.69 ) Ranked among companies with meaningful PS Ratio only. |
AVDL'
s PS Ratio Range Over the Past 10 Years
Min: 1.67 Med: 4.68 Max: 799.47 Current: 1.69 |
| Price-to-Operating-Cash-Flow | 18.84 |
AVDL's Price-to-Operating-Cash-Flow is ranked higher than
88% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 30.32 vs. AVDL: 18.84 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
AVDL'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79 Med: 17.68 Max: 49.71 Current: 18.84 |
| EV-to-EBIT | 1.83 |
AVDL's EV-to-EBIT is ranked higher than
90% of the 262 Companies in the Global Biotechnology industry. ( Industry Median: 24.43 vs. AVDL: 1.83 ) Ranked among companies with meaningful EV-to-EBIT only. |
AVDL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -88.3 Med: -7.1 Max: 89.5 Current: 1.83 |
| EV-to-EBITDA | 1.73 |
AVDL's EV-to-EBITDA is ranked higher than
92% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 21.70 vs. AVDL: 1.73 ) Ranked among companies with meaningful EV-to-EBITDA only. |
AVDL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -304 Med: -6.6 Max: 76.3 Current: 1.73 |
| EV-to-Revenue | 0.99 |
AVDL's EV-to-Revenue is ranked higher than
96% of the 777 Companies in the Global Biotechnology industry. ( Industry Median: 13.46 vs. AVDL: 0.99 ) Ranked among companies with meaningful EV-to-Revenue only. |
AVDL'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1 Med: 4.1 Max: 248 Current: 0.99 |
| Current Ratio | 1.43 |
AVDL's Current Ratio is ranked lower than
80% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 4.21 vs. AVDL: 1.43 ) Ranked among companies with meaningful Current Ratio only. |
AVDL'
s Current Ratio Range Over the Past 10 Years
Min: 0.83 Med: 2.89 Max: 6.76 Current: 1.43 |
| Quick Ratio | 1.36 |
AVDL's Quick Ratio is ranked lower than
77% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 3.92 vs. AVDL: 1.36 ) Ranked among companies with meaningful Quick Ratio only. |
AVDL'
s Quick Ratio Range Over the Past 10 Years
Min: 0.77 Med: 2.83 Max: 6.7 Current: 1.36 |
| Days Inventory | 118.40 |
AVDL's Days Inventory is ranked higher than
53% of the 498 Companies in the Global Biotechnology industry. ( Industry Median: 126.17 vs. AVDL: 118.40 ) Ranked among companies with meaningful Days Inventory only. |
AVDL'
s Days Inventory Range Over the Past 10 Years
Min: 51.05 Med: 100.4 Max: 1457.72 Current: 118.4 |
| Days Sales Outstanding | 31.15 |
AVDL's Days Sales Outstanding is ranked higher than
64% of the 656 Companies in the Global Biotechnology industry. ( Industry Median: 64.11 vs. AVDL: 31.15 ) Ranked among companies with meaningful Days Sales Outstanding only. |
AVDL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.8 Med: 69.78 Max: 541.87 Current: 31.15 |
| Days Payable | 167.42 |
AVDL's Days Payable is ranked higher than
83% of the 456 Companies in the Global Biotechnology industry. ( Industry Median: 62.86 vs. AVDL: 167.42 ) Ranked among companies with meaningful Days Payable only. |
AVDL'
s Days Payable Range Over the Past 10 Years
Min: 161.48 Med: 228.67 Max: 3311.63 Current: 167.42 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 21.20 |
AVDL's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 768 Companies in the Global Biotechnology industry. ( Industry Median: -13.20 vs. AVDL: 21.20 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
AVDL'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7 Med: -7.8 Max: 21.2 Current: 21.2 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 3.69 | ||
| Price-to-Median-PS-Value | 0.36 |
AVDL's Price-to-Median-PS-Value is ranked higher than
89% of the 614 Companies in the Global Biotechnology industry. ( Industry Median: 1.00 vs. AVDL: 0.36 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
AVDL'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36 Med: 1.09 Max: 16.79 Current: 0.36 |
| Earnings Yield (Greenblatt) % | 54.86 |
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1060 Companies in the Global Biotechnology industry. ( Industry Median: -6.86 vs. AVDL: 54.86 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
AVDL'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.5 Med: -7.8 Max: 56.1 Current: 54.86 |
| Revenue (TTM) (Mil) $ | 173.25 |
|---|---|
| EPS (TTM) $ | 1.63 |
| Beta | 2.39 |
| Volatility | 49.67% |
| 52-Week Range $ | 6.71 - 11.93 |
| Shares Outstanding (Mil) | 37.95 (ADR) |
| Dec18 | Dec19 | Dec20 | |
|---|---|---|---|
| Revenue (Mil $) | 118 | 134 | 217 |
| EBIT (Mil $) | |||
| EBITDA (Mil $) | |||
| EPS ($) | -1.30 | -0.75 | 0.50 |
| EPS without NRI ($) | -1.30 | -0.75 | 0.50 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
| Dividends per Share ($) | |||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP